217 results on '"Connors, Joseph M."'
Search Results
2. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
3. The outcome of older adults with classic Hodgkin lymphoma in British Columbia
4. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach
5. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
6. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
7. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach
8. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
9. Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray
10. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
11. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
12. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
13. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
14. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
15. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact
16. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
17. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma
18. 172 - Hodgkin Lymphoma
19. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
20. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL
21. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis
22. Cell of origin of transformed follicular lymphoma
23. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
24. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
25. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma
26. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
27. An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
28. Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma
29. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
30. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma
31. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
32. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
33. Treatment and Outcomes in Patients With Primary Cutaneous B-Cell Lymphoma: The BC Cancer Agency Experience
34. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
35. Non-Hodgkin lymphoma: the clinician's perspective—a view from the receiving end
36. Treatment and Outcomes of Primary Breast Lymphoma
37. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
38. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
39. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
40. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
41. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project
42. Contributors
43. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
44. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation
45. Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
46. Cooperative Epigenetic Modulation by Cancer Amplicon Genes
47. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
48. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
49. Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma
50. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.